ArticleJournal of food and drug analysis2024
A novel selective medium for isolation of Limosilactobacillus reuteri from dietary supplements.
Article in Journal of food and drug analysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limosilactobacillus reuteri is a probiotic bacterium known for its numerous beneficial effects on human health and is commonly utilized in various dietary supplements. Previously, we encountered difficulties in isolating L. reuteri from retail dietary supplements containing complex probiotic compositions by using non-selective media such as de Man, Rogosa, and Sharpe (MRS) agar. Our findings reveal that MRS agar with d-gluconic acid as the carbon source and peptone from soymeal as the nitrogen source provides a growth advantage for L. reuteri. Furthermore, all the tested L. reuteri strains exhibit higher resistance to oxacillin compared with non-L. reuteri strains, and the recovery of L. reuteri is significantly higher than that of non-L. reuteri strains on modified MRS agar (MRS-GSOT agar) supplemented with either 4 or 10 μg/mL oxacillin. Results of spiking tests indicate that MRS-GSOT agar with 10 μg/mL oxacillin can selectively inhibit the growth of species other than L. reuteri in single culture or mixed bacterial broth within food matrices. However, the recovery of L. reuteri is relatively low when subjected to the spiking tests with various ratios of non- L. reuteri. Testing results of 15 retail dietary supplements also show that MRS-GSOT agar could efficiently isolate L. reuteri from retail dietary supplements with complex compositions of probiotic bacteria. In addition, we observe that L. reuteri exhibits two different colony morphologies on MRS-GSOT agar with 10 μg/mL oxacillin, yet they shared a common feature: a noticeable metallic (golden) sheen on the colony surface when the plate is slightly tilted, which can be used to distinguish them from non-L. reuteri species, such as Lactiplantibacillus plantarum subsp. plantarum, Levilactobacillus brevis, and Bifidobacterium longum subsp. longum. In conclusion, we have developed MRS-GSOT agar containing d-gluconic acid, peptone from soymeal, oxacillin, and 2,3,5-triphenyltetrazolium chloride for efficient isolation of L. reuteri from dietary supplements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.